Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis Report 2017 - Research and Markets
FDA Lifts Clinical Hold on Seattle Genetics ’ Phase 1 Trials of Vadastuximab Talirine
March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics , Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
Investor Alert: GPM Reminds Investors of the March 13 Deadline in the Class Action Lawsuit Against Seattle Genetics , Inc.
This Gold-rated fund is a fine vehicle for new investors to gain access to the Primecap managers.
Health-care stocks are on a tear as demand slowly returns.
The five biotech ETFs have very different portfolios with markedly different performance.
While we remain bullish on the sector, health-care growth depends on the economy.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.